Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03506373 · OUTCOME

Progression-free Survival

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia · Source last updated 2026-05-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From study registration to the earliest date of documentation of disease progression, assessed up to 5 years

What was measured

The median time to progression will be estimated using the method of Kaplan-Meier. Categorized by Response Assessment Criteria as specified in Appendix III of the protocol.

Groups in this outcome

Treatment (Ixazomib Citrate, Ibrutinib)

Patients receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. \> \> Ibrutinib: Given PO \> \> Ixazomib Citrate: Given PO \> \> Laboratory Biomarker Analysis: Correlative studies \> \> Pharmacodynamic Study: Correlative studies \> \> Pharmacokinetic Study: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Ixazomib Citrate, Ibrutinib)21

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Ixazomib Citrate, Ibrutinib)22.9Not reported17.2NAThe upper limit of the CI is not estimable due to a low number of events
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        The upper limit of the CI is not estimable due to a low number of events
        group Id
        OG000
        lower Limit
        17.2
        upper Limit
        NA
        value
        22.9
denoms
  1. counts
    1. group Id
      OG000
      value
      21
    units
    Participants
description
The median time to progression will be estimated using the method of Kaplan-Meier. Categorized by Response Assessment Criteria as specified in Appendix III of the protocol.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. \> \> Ibrutinib: Given PO \> \> Ixazomib Citrate: Given PO \> \> Laboratory Biomarker Analysis: Correlative studies \> \> Pharmacodynamic Study: Correlative studies \> \> Pharmacokinetic Study: Correlative studies
    id
    OG000
    title
    Treatment (Ixazomib Citrate, Ibrutinib)
param Type
MEDIAN
reporting Status
POSTED
time Frame
From study registration to the earliest date of documentation of disease progression, assessed up to 5 years
title
Progression-free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice